Biocytogen Pharmaceuticals (beijing) Co., Ltd.

Eucure (beijing) Biopharma Co., Ltd.

Biocytogen Jiangsu Co., Ltd.

Beijing University of Technology

Beijing Biocytogen Co., Ltd

Biocytogen Pharmaceuticals Co., Ltd.

Yanan Guo

Yuelei Shen

Rui Huang

Yang Bai

Jiawei Yao

Meiling Zhang

Jian Ni

Xiaofei Zhou

Chaoshe Guo

Chen Wang

Fang Yang

Chengyuan Lu

Yunyun Chen

Jingshu Xie

Chunyan Dong

Lei Zhao

Chengzhang Shang

Xiaodong Cheng

Junfei Qiao

Honggui Han

Yuting Hu

Jichao Du

The present disclosure relates to the genetically modified non-human animals that have a disruption at the endogenous CD132 gene (e.g., CD132 knockout), and methods of use thereof

Immunodeficient non-human animal

This disclosure relates to anti-PD-1 (Programmed Cell Death Protein 1) antibodies, antigen-binding fragments, and the uses thereof.

Anti-PD-1 antibodies and methods of treating cancer

This disclosure relates to anti-CD40 (TNF Receptor Superfamily Member 5) antibodies, antigen-binding fragments, and the uses thereof.

Anti-CD40 antibodies and uses thereof

This disclosure relates to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4 or CTLA-4) antibodies, antigen-binding fragments, and the uses thereof.

Anti-CTLA4 antibodies and uses thereof

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD3e (T-cell surface glycoprotein CD3 epsilon chain), and methods of use thereof.

Genetically modified non-human animal with human or chimeric CD3e

This disclosure relates to anti-human OX40 (TNF Receptor Superfamily Member 4, or TNFRSF4) antibodies, antigen-binding fragments, and the uses thereof.

Anti-OX40 antibodies and uses thereof

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD47, and methods of use thereof.

Genetically modified mice expressing humanized CD47

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) LAG3, and methods of use thereof.

Genetically modified non-human animal with human or chimeric LAG3

The present disclosure relates to the genetically modified non-human animals that express a human or chimeric TIGIT (e.g., humanized TIGIT), and methods of use thereof.

Genetically modified non-human animal with human or chimeric TIGIT

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD40, and methods of use thereof.

Genetically modified mice expressing humanized CD40

Genetically modified mouse comprising a chimeric TIGIT

Provided are a humanized transgenic non-human animal, especially a rodent, in particular a transgenic mouse containing a human interleukin 17A (IL-17A) gene, a human gene 17RA (IL-17RA) and/or a human TNF-alpha gene, and a preparation method therefor and the use thereof.

Humanized transgenic animal

Anti-PD-1 antibodies and uses thereof

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD28, and methods of use thereof.

Genetically modified non-human animal with human or chimeric CD28

Under conventional techniques, wastewater treatment has many problems such as poor production conditions, serious random interference, strong nonlinear behavior, large time-varying, and serious lagging. These problems cause difficulty in detecting wastewater treatment parameters such as biochemical oxygen demand (BOD) values that are used to monitor water quality. To solve problems associated with monitoring BOD values in real-time, the present disclosure utilizes a self-organizing recurrent RBF neural network designed for intelligent detecting of BOD values. Implementations of the present disclosure build a computing model of BOD values based on the self-organizing recurrent RBF neural network to achieve real-time and more accurate detection of the BOD values (e.g., a BOD concentration). The implementations herein quickly and accurately obtain BOD concentrations and improve the quality and efficiency of wastewater treatment.

Growing community of inventors

Beijing, China

Yanan Guo